Evolus (EOLS) Return on Capital Employed (2018 - 2026)
Evolus (EOLS) reported Return on Capital Employed of 15.68% for Q1 2026, up 871.0% on a YoY basis from 1.61% in Q1 2025, and up 29.38% quarter-over-quarter from 22.2% in Q4 2025.
Evolus (EOLS) Return on Capital Employed (2018 - 2026) Analysis & Trends
Evolus has reported Return on Capital Employed for 9 years, with the latest figure at 15.68% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 871.0% year-over-year to 15.68%; the trailing twelve-month figure through Mar 2026 stood at 15.68% (up 871.0% YoY), and the FY2025 full-year result was 21.22%, up 206.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 15.68%, up from 22.2% in the prior quarter.
- The five-year high for Return on Capital Employed was 15.68% in Q1 2026, with the low at 48.3% in Q3 2022.
- Historically, Return on Capital Employed has averaged 32.83% across 5 years, with a median of 28.68% in 2024.
- The largest YoY upside for Return on Capital Employed was 9946 bps in 2022 against a maximum downside of 2220 bps in 2022.
- Evolus' Return on Capital Employed stood at 47.05% in 2022, then grew by 20 bps to 37.82% in 2023, then jumped by 46 bps to 20.47% in 2024, then dropped by 8 bps to 22.2% in 2025, then gained by 29 bps to 15.68% in 2026.
- The last three Return on Capital Employed figures came in at 15.68% (Q1 2026), 22.2% (Q4 2025), and 24.94% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 8.52% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 27.58% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 21.43% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 20.04% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 7.34% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 6.92% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -1.92% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 14.85% |
| 10 | Evolus | 437.40 Mn | 387.61 Mn | 48.90 Mn | -15.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.68% |
| Dec 31, 2025 | -22.20% |
| Sep 30, 2025 | -24.94% |
| Jun 30, 2025 | -27.44% |
| Mar 31, 2025 | -24.39% |
| Dec 31, 2024 | -20.47% |
| Sep 30, 2024 | -23.84% |
| Jun 30, 2024 | -22.01% |
| Mar 31, 2024 | -28.68% |
| Dec 31, 2023 | -37.82% |
| Sep 30, 2023 | -42.72% |
| Jun 30, 2023 | -45.18% |
| Mar 31, 2023 | -48.21% |
| Dec 31, 2022 | -47.05% |
| Sep 30, 2022 | -48.30% |
| Jun 30, 2022 | -45.01% |
| Mar 31, 2022 | -34.22% |
| Dec 31, 2021 | -24.85% |
| Sep 30, 2021 | -86.02% |
| Jun 30, 2021 | -111.51% |